Anbio Biotechnology Class A Ordinary Shares (NNNN) Price Target Analysis

Analyst Rating:

Based on 0 analysts

No Target Data

NNNN trades at Wall Street's consensus target of —.

Current Price$15.30

Average Target—

Low—

Median—

High—

Analyst Target Range

Forward P/E—

PEG Ratio—

Implied Growth—

Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$15.30

Consensus—

High—

Low—

Consensus Scenario Assumptions

The base valuation assumes NNNN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings

No analyst coverage available for NNNN

Coverage appears once Wall Street estimates are published.

NNNN Price Target Analysis

Updated June 28, 2026

As of June 28, 2026, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $672M.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.

From a valuation perspective, NNNN trades at a trailing P/E of 95.6x.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.63, with bear and bull scenarios of $4.18 and $8.73 respectively. Model confidence stands at 35/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis

Avg Peer Upside

+7.2%

Industry Consensus

Avg Forward P/E

35.1x

(Growth Premium)

Peers with Coverage

9 / 10

Active Analyst Tracking

Company	Market Cap	Price	Target	Upside Potential	Rating	Fwd P/E	Analysts
CLOVClover Health Investments, Corp.	$2.8B	$5.41	$4.47	-17.4%	Hold	139.8x	9
ACHCAcadia Healthcare Company, Inc.	$2.5B	$27.42	$28.33	+3.3%	Buy	18.2x	25
QDELQuidelOrtho Corporation	$939M	$13.79	$12.25	-11.2%	Hold	7.5x	15
CHEKCheck-Cap Ltd.	$11M	$1.86	—	—	—	—	—
IDXXIDEXX Laboratories, Inc.	$43.8B	$551.50	$747.50	+35.5%	Buy	37.6x	22
BIOBio-Rad Laboratories, Inc.	$8.1B	$300.79	$321.67	+6.9%	Buy	33.3x	14
NEOGNeogen Corporation	$2.1B	$9.58	$11.00	+14.8%	Hold	25.9x	11
ALGNAlign Technology, Inc.	$12.8B	$178.43	$203.60	+14.1%	Buy	15.7x	33
HOLXHologic, Inc.	$17.0B	$76.01	$78.69	+3.5%	Hold	17.2x	42
TMOThermo Fisher Scientific Inc.	$190.7B	$513.03	$592.45	+15.5%	Buy	20.6x	42

NNNN — Frequently Asked Questions

Quick answers to the most common questions about buying NNNN stock.

What is the NNNN stock price target for 2026?

The consensus price target for NNNN is $N/A, close to the current price of $15.3 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.

Is NNNN a buy, sell, or hold?

NNNN has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is NNNN stock overvalued or undervalued?

NNNN's current price is $15.3 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.

How high can NNNN stock go?

The most bullish Wall Street analyst has a price target of $N/A for NNNN, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $9 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover NNNN stock?

NNNN is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the NNNN stock forecast?

The 12-month NNNN stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A". Our proprietary valuation model produces a base case fair value of $7, with bear/bull scenarios of $4/$9.

What is NNNN's fair value based on fundamentals?

Our quantitative valuation model calculates NNNN's fair value at $7 (base case), with a bear case of $4 and bull case of $9. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 35/100.

Should I buy NNNN stock?

NNNN appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do NNNN price targets vary so much?

NNNN analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $4-$9 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools